```html

Jelling’s Disease (Dent’s Disease) – A Comprehensive Patient Guide

Overview

Jelling’s disease, more commonly known as **Dent’s disease**, is a rare, inherited kidney disorder that primarily affects the proximal tubules of the nephron. The condition leads to excessive loss of proteins, phosphate, calcium, and other small molecules in the urine (proteinuria and phosphaturia), eventually causing kidney damage and progressive renal insufficiency.

Who it affects: The disease is X‑linked recessive, meaning the defective gene is located on the X chromosome. It therefore predominates in males, who have only one X chromosome, while females are usually carriers and may have mild or no symptoms.

Prevalence: Exact global figures are uncertain because many cases go undiagnosed, but epidemiologic studies estimate a prevalence of 1–5 per million males worldwide. In the United States, the National Kidney Foundation reports roughly 300–500 diagnosed males, with additional undetected cases likely present.<sup>1</sup>

Symptoms

The clinical presentation can be highly variable, even among members of the same family. Below is a comprehensive list of reported symptoms, grouped by organ system.

Renal (Kidney‑related) Symptoms

• Low‑molecular‑weight proteinuria: Persistent loss of proteins such as β2‑microglobulin and retinol‑binding protein in the urine.
• Hypercalciuria: Excess calcium in the urine, often the first laboratory clue.
• Nephrocalcinosis: Deposition of calcium salts in the renal parenchyma, visible on imaging.
• Kidney stones (nephrolithiasis): Recurrent calcium‑based stones, especially calcium oxalate.
• Progressive renal insufficiency: Declining glomerular filtration rate (GFR) over years, potentially culminating in end‑stage renal disease (ESRD) in the third to fifth decade of life.

Metabolic & Electrolyte Symptoms

• Phosphaturia & hypophosphatemia: Low serum phosphate leading to bone demineralization.
• Rickets or osteomalacia: Bone pain, fractures, and growth retardation in children.
• Elevated parathyroid hormone (secondary hyperparathyroidism): Resulting from chronic phosphate loss.
• Metabolic acidosis (rare): Mild to moderate acid‑base disturbance.

Other Possible Features

• Proteinuria unrelated to glomerular disease (often misdiagnosed as “idiopathic” proteinuria).
• Persistent urinary tract infections secondary to stone disease.
• Mild anemia as kidney function declines.
• In rare cases, ocular abnormalities (e.g., cataracts) have been reported in association with certain CLCN5 mutations.

Causes and Risk Factors

Dent’s disease is caused by pathogenic variants in genes that encode proteins essential for proximal tubular transport.

Genetic Causes

• CLCN5 (chloride channel 5) mutations: Account for ~60–70 % of cases. The protein functions as a voltage‑gated chloride channel important for endosomal acidification and protein reabsorption.
• OCRL1 (oculocerebrorenal syndrome of Lowe) mutations: Found in ~10 % of patients, overlapping with the phenotype of Lowe syndrome.
• Other rare genes: ATP6V1C2, PDK1, and recently identified MGARP variants have been implicated in a handful of families.

Who Is at Risk?

• Male infants or children: Because the disease is X‑linked, a male who inherits the mutant gene will manifest the disease.
• Female carriers: Usually asymptomatic but can exhibit mild proteinuria or hypercalciuria; they are at risk of passing the mutation to offspring.
• Family history: A known relative with Dent’s disease or unexplained early‑onset kidney stones should prompt genetic counseling.
• Ethnicity: No specific ethnic predilection has been identified, though most reported cases are from European‑derived populations—likely an ascertainment bias.

Diagnosis

Diagnosing Dent’s disease requires a combination of clinical suspicion, laboratory tests, imaging, and genetic confirmation.

Step‑by‑step Diagnostic Approach

1. Clinical history & physical exam: Recurrent kidney stones, persistent proteinuria, growth issues in children, and a family history of X‑linked kidney disease raise suspicion.
2. Urine analysis:
   • Quantify low‑molecular‑weight proteinuria (β2‑microglobulin, retinol‑binding protein).
   • Measure urinary calcium/creatinine ratio – elevated in >80 % of males.
   • Assess phosphate excretion (TmP/GFR) – often reduced.
3. Blood tests:
   • Serum phosphate (often low), calcium (normal or high), creatinine, and eGFR.
   • Parathyroid hormone (PTH) and vitamin D levels for secondary hyperparathyroidism.
4. Imaging:
   • Renal ultrasound to detect nephrocalcinosis or stones.
   • Non‑contrast CT if stone burden is high.
5. Genetic testing: Targeted sequencing of CLCN5 and OCRL1 genes (or a kidney‑disease gene panel) confirms the diagnosis. The American College of Medical Genetics (ACMG) recommends genetic confirmation for definitive diagnosis and family counseling.<sup>2</sup>
6. Kidney biopsy (rarely needed): May be performed when the diagnosis is unclear; findings typically show tubular atrophy with minimal glomerular changes.

Diagnostic Criteria (Simplified)

Most experts accept a diagnosis when three of the following are present:

• Low‑molecular‑weight proteinuria.
• Hypercalciuria.
• Nephrocalcinosis or kidney stones.
• Elevated urinary β2‑microglobulin.
• Confirmed pathogenic variant in CLCN5 or OCRL1.

Treatment Options

At present, no cure exists; therapy focuses on slowing kidney damage, preventing stones, and correcting metabolic abnormalities.

Medication‑Based Therapies

• Thiazide diuretics: Reduce urinary calcium excretion and lower stone risk. Typical dose: hydrochlorothiazide 12.5–25 mg daily.<sup>3</sup>
• Potassium citrate: Alkalinizes urine, inhibits calcium stone formation, and may improve bone health. Dose usually 30–60 mEq divided 2–3 times daily.
• Phosphate supplements: Oral phosphate (e.g., sodium phosphate) or phosphate‑rich diets for children with severe hypophosphatemia; dosing guided by serum levels.
• Vitamin D analogs (calcitriol): Used cautiously to treat secondary hyperparathyroidism, balancing the risk of hypercalciuria.
• Angiotensin‑converting enzyme (ACE) inhibitors or ARBs: May reduce proteinuria and protect renal function, though evidence specific to Dent’s disease is limited.

Procedural & Surgical Interventions

• Extracorporeal shock wave lithotripsy (ESWL) or ureteroscopy: For symptomatic kidney stones.
• Percutaneous nephrolithotomy (PCNL): Indicated for large or staghorn calculi.
• Renal transplantation: Considered when ESRD develops (average age 30–40 years). Post‑transplant outcomes are comparable to other hereditary nephropathies.

Lifestyle and Dietary Modifications

• Maintain a **fluid intake** of ≥ 2.5–3 L/day (unless contraindicated) to dilute urinary solutes.
• Adopt a **low‑oxalate, moderate‑calcium diet** (800‑1,000 mg calcium/day) to reduce stone formation.
• Limit **sodium** (<2 g/day) to decrease calcium excretion.
• Avoid **high‑protein** (especially animal protein) diets that increase calcium and uric acid load.
• Regular **weight‑bearing exercise** to support bone mineral density.

Living with Jelling’s Disease (Dent’s Disease)

Effective self‑management empowers patients to maintain quality of life and postpone kidney failure.

Daily Management Checklist

1. Medication adherence: Use a weekly pill organizer; set reminders.
2. Fluid tracking: Carry a reusable bottle with volume markings.
3. Urine monitoring: Periodic dip‑stick testing for calcium crystals or blood (especially after stone events).
4. Lab follow‑up: Serum creatinine, eGFR, phosphate, calcium, and PTH every 6–12 months (more often if progressive).
5. Bone health: DEXA scan every 2–3 years; discuss calcium/vitamin D supplementation with your physician.
6. Genetic counseling: Essential for affected men planning families and for carrier‑testing of female relatives.
7. Psychosocial support: Connect with patient advocacy groups (e.g., Rare Kidney Stone Foundation) for emotional coping and up‑to‑date research.

Tips for School/Work

• Keep a **hydration plan**—have water bottles at the desk and set hourly drinking reminders.
• Store a **small medication kit** (thiazide, potassium citrate) in a locker or bag.
• Inform teachers or supervisors about the need for **frequent bathroom breaks** to avoid dehydration.

Prevention

Because Dent’s disease is genetic, primary prevention of the disorder itself is not possible. However, secondary prevention—reducing disease‑related complications—is achievable.

• **Early genetic screening** of at‑risk families enables prompt monitoring.
• **Adequate hydration** and dietary measures lower stone risk.
• **Timely treatment of hypercalciuria** with thiazides prevents nephrocalcinosis.
• **Regular renal imaging** can detect early calcifications before they cause obstruction.
• **Vaccinations** (influenza, pneumococcal) reduce infection‑related kidney stress, especially in later stages.

Complications

If left untreated or poorly managed, Dent’s disease can lead to several serious outcomes.

• End‑Stage Renal Disease (ESRD): Occurs in about 30–50 % of males by age 40–50; dialysis or transplantation required.
• Recurrent nephrolithiasis: May cause obstruction, infection, and acute kidney injury.
• Bone disease: Rickets in children; osteomalacia or osteoporosis in adults due to chronic phosphate loss.
• Secondary hyperparathyroidism: Can exacerbate bone demineralization and calcium imbalance.
• Hypertension: Progressive renal scarring may elevate blood pressure.
• Cardiovascular risk: Chronic kidney disease increases risk of heart disease and stroke.

When to Seek Emergency Care

Key Take‑aways

• Dent’s disease (Jelling’s disease) is a rare X‑linked kidney tubulopathy causing proteinuria, hypercalciuria, and progressive renal decline.
• Genetic testing for CLCN5 or OCRL1 confirms the diagnosis and guides family counseling.
• Management hinges on thiazide diuretics, potassium citrate, phosphate repletion, and rigorous hydration.
• Regular monitoring, early stone prevention, and bone health surveillance can delay ESRD.
• Seek emergency care for acute pain, fever, sudden oliguria, or hypertensive crises.

For personalized advice, always consult a nephrologist familiar with hereditary tubulopathies. Reputable resources include the Mayo Clinic, CDC, NIH, and the New England Journal of Medicine.

```